RxDoctor Payments Data

Ronak Vora, DO

Neurology · Mission Viejo, CANPI 1942560321

Payments from drug & device makers

$12,432in general payments, 2019–2025

Across 642 payments — averaging $19.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Biogen$934
  • Acadia Pharmaceuticals Inc$917
  • Boston Scientific$561
  • SK Life Science, Inc.$544
  • Abbott$355
  • plus $5K from 53 others

What the payments were for

  • Speaking & faculty fees$450%
  • Travel & lodging$2612%
  • Food & beverage$12,11997%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)264$3,823
Biogen52$934
Acadia Pharmaceuticals Inc36$917
Boston Scientific9$561
SK Life Science, Inc.24$544
Abbott8$355
UCB, Inc.18$353
Medtronic(2 entities)10$336
MDD US Operations, LLC13$329
Teva Pharmaceuticals USA, Inc.15$293
Adamas Pharmaceuticals, Inc.14$292
Lundbeck LLC14$281
Sunovion Pharmaceuticals Inc.18$278
Lilly USA, LLC14$252
Novartis10$225
Biohaven Pharmaceuticals, Inc.10$179
Argenx US, Inc.7$173
AstraZeneca(2 entities)8$172
Sanofi7$149
Genentech USA, Inc.6$129
Amneal Pharmaceuticals LLC5$114
Avion Pharmaceuticals5$114
Pfizer5$111
Amgen(2 entities)4$107
Neurelis, Inc.4$103
Biohaven Pharmaceutical Holding Company Ltd.4$84
Harmony Biosciences LLC3$78
Corium, LLC3$76
Aquestive Therapeutics, Inc.4$74
Averitas Pharma Inc.3$70
Livanova USA, Inc.3$68
Kyowa Kirin, Inc.3$65
Portola Pharmaceuticals, LLC2$50
Cycle Pharmaceuticals Inc2$48
Supernus Pharmaceuticals, Inc.3$48
Acorda Therapeutics, Inc2$45
Eisai Inc.2$42
Upsher-smith Laboratories LLC2$41
Neuropace, Inc.2$37
GE HealthCare1$37
Johnson & Johnson(2 entities)2$33
Assertio Therapeutics, Inc.2$33
Neurocrine Biosciences, Inc.2$30
Cala Health, Inc.1$30
Ipsen Biopharmaceuticals, Inc1$29
Merz Pharmaceuticals, LLC1$27
CSL Behring2$26
Alnylam Pharmaceuticals Inc.1$24
Noctrix Health, Inc.1$24
Tanabe Pharma America, Inc.1$24
TG Therapeutics, Inc.1$22
Bristol Myers Squibb1$21
Grifols USA, LLC1$20
Banner Life Sciences, LLC1$19
Aucta Pharmaceuticals, Inc.1$18
Vertical Pharmaceuticals, LLC1$18
Otsuka America Pharmaceutical, Inc.1$18
GRT US Holding, Inc.1$14
Zyla Life Sciences, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,432 in reported general payments places this provider in the 75th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$271,329
Medicare patients
474
Services billed
14,831

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate62$397,014
RytaryCarbidopa/Levodopa57$78,034
NeuproRotigotine44$50,162
InbrijaLevodopa25$40,977
Droxidopa15$38,835
Carbidopa-LevodopaCarbidopa/Levodopa572$24,553
NourianzIstradefylline13$23,743
Rasagiline Mesylate47$15,564
Memantine Hcl289$13,062
Aimovig AutoinjectorErenumab-Aooe18$12,887
AmantadineAmantadine Hcl103$10,923
Ropinirole Hcl173$7,655
Carbidopa-Levodopa ErCarbidopa/Levodopa103$6,898
Midodrine Hcl40$5,282
Gabapentin144$4,985

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$917$397,01462 claims
Amneal Pharmaceuticals LLCRytary$114$78,03457 claims
UCB, Inc.Neupro$353$50,16244 claims
Acorda Therapeutics, IncInbrija$45$40,97725 claims
Kyowa Kirin, Inc.Nourianz$65$23,74313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,996 neurology providers in California.

Other neurology in Mission Viejo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →